ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Especially, before the advent and breakthrough of the BCR-ABL inhibitor imatinib as therapy for chronic myeloid leukemia (CML), IFNα was the treatment of choice for patients not suitable for bone marrow transplantation.